Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Oct 10;30(Suppl 2):II-24–II-34. doi: 10.1002/clc.20238

Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk

Steven V Manoukian 1,✉, Michele D Voeltz 1, John Eikelboom 2
PMCID: PMC6653476  PMID: 18228649

Abstract

In clinical trials up to 30% of patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI) experience bleeding complications, and even higher rates have been reported in contemporary practice. A growing body of data suggests a strong correlation between bleeding and both short‐ and long‐term adverse outcomes, including mortality, which is independent of baseline characteristics and remains evident in most trials, despite variations in the definition of major bleeding. Although the value of antithrombin and antiplatelet therapy in reducing the risk of ischemic events is well established, the mechanisms of action that confer the benefits of these therapies have an inherent tendency to increase the risk of bleeding complications. As a result, characterization of baseline hemorrhagic risk is critical and must be accomplished before selecting an antithrombotic therapy. Risk factors for bleeding may be divided into two categories: nonmodifiable (including age, gender, race, weight, renal insufficiency, anemia, and acuity of presentation) and modifiable (including choice of antithrombotic therapy and PCI procedural characteristics). Of these predictive factors, the choice, dosage, and duration of the antithrombin and/or antiplatelet regimen are perhaps the most readily modifiable, especially in patients with an increased risk of bleeding. This review explores the nature of the association between bleeding and adverse outcomes, including mortality; evaluates risk factors for bleeding; and examines mechanisms for reducing bleeding complications through the selection of appropriate antithrombotic therapy. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: bleeding complications, percutaneous coronary intervention, acute coronary syndromes, risk factors, heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors, low‐molecular‐weight heparin, hemorrhage, transfusion

Full Text

The Full Text of this article is available as a PDF (312.4 KB).

References

  • 1. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, et al: CRUSADE Investigators : The implications of blood transfusions for patients with non–st‐segment elevation acute coronary syndromes: results from the crusade national quality improvement initiative. J Am Coll Cardiol 2005; 46: 1490–1495. [DOI] [PubMed] [Google Scholar]
  • 2. EPILOG Investigators : Platelet glycoprotein IIb/IIIa receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696. [DOI] [PubMed] [Google Scholar]
  • 3. EPISTENT Investigators : Randomised placebo‐controlled and balloon‐angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein‐IIb/IIIa blockade. Lancet 1998; 352: 87–92. [DOI] [PubMed] [Google Scholar]
  • 4. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, et al: Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial Investigators : Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907–919. [DOI] [PubMed] [Google Scholar]
  • 5. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators : Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464–1476. [DOI] [PubMed] [Google Scholar]
  • 6. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, et al., SYNERGY Trial Investigators : Enoxaparin vs unfractionated heparin in high‐risk patients with non–ST‐segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54. [DOI] [PubMed] [Google Scholar]
  • 7. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, et al.: Impact of major bleeding on 30‐day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362–1368. [DOI] [PubMed] [Google Scholar]
  • 8. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, et al., CRUSADE Investigators : Excess dosing of antiplatelet and antithrombin agents in the treatment of non–ST‐segment elevation acute coronary syndromes. JAMA 2005; 294: 3108–3116. [DOI] [PubMed] [Google Scholar]
  • 9. Milkovich G, Gibson G: Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60(Suppl 3): S15–S21. [DOI] [PubMed] [Google Scholar]
  • 10. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, et al.: Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–782. [DOI] [PubMed] [Google Scholar]
  • 11. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930–935. [DOI] [PubMed] [Google Scholar]
  • 12. Nelson MA, Voeltz MD, Feit F, Lincoff AM, Manoukian SV: Elderly patients with major bleeding or need for transfusion complicating percutaneous coronary intervention have an increased risk of 30‐day and 1‐year mortality. Circulation 2006; 114: II–687. [Google Scholar]
  • 13. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, et al., REPLACE‐2 Investigators : Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE‐2 trial). Am J Cardiol 2005; 95: 581–585. [DOI] [PubMed] [Google Scholar]
  • 14. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, et al.: Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003; 108: 2769–2775. [DOI] [PubMed] [Google Scholar]
  • 15. Moscucci M, Fox KA, Cannon CP, Klein W, López‐Sendón J, et al.: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–1823. [DOI] [PubMed] [Google Scholar]
  • 16. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, et al., TIMI Study Group : Correlates of bleeding events among moderate‐ to high‐risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT‐TIMI‐30 trial. J Am Coll Cardiol 2006; 47: 2374–2379. [DOI] [PubMed] [Google Scholar]
  • 17. McDaniel MC, Fazel R, Voeltz MD, Feit F, Lincoff AM, et al.: Eptifibatide plus heparin increases the risk of major and minor hemorrhagic complications compared to bivalirudin in patients with normal renal function undergoing percutaneous coronary intervention. Circulation 2006; 114: II–731. [Google Scholar]
  • 18. Voeltz MD, Feit F, Stone GW, Manoukian SV: Anemia and outcomes in acute coronary syndromes. Acute Coron Synd 2005; 7: 47–55. [Google Scholar]
  • 19. Voeltz MD, Patel AD, Feit F, Fazel R, Lincoff AM, et al.: Effect of anemia on hemorrhagic complications and mortality in patients undergoing percutaneous coronary Intervention. Am J Cardiol 2007; 99: 1513–1517. [DOI] [PubMed] [Google Scholar]
  • 20. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, et al.: Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042–2049. [DOI] [PubMed] [Google Scholar]
  • 21. Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, et al.: Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. Am J Med 2006; 119: 70.e1–e8. [DOI] [PubMed] [Google Scholar]
  • 22. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, et al.: Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995; 91: 2882–2890. [DOI] [PubMed] [Google Scholar]
  • 23. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, et al.: Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 1998; 81: 36–40. [DOI] [PubMed] [Google Scholar]
  • 24. Voeltz MD, Nelson MA, McDaniel MC, Manoukian SV: The important properties of contrast media: focus on viscosity. J Invasive Cardiol 2007; 19(A): 1A–9A. [PubMed] [Google Scholar]
  • 25. Hamon M, Sabatier R, Zhao Q, Niculescu R, Valette B, et al.: Mini‐invasive strategy in acute coronary syndromes: direct coronary stenting using 5 Fr guiding catheters and transradial approach. Catheter Cardiovasc Interv 2002; 55: 340–343. [DOI] [PubMed] [Google Scholar]
  • 26. Attubato MJ, Feit F, Bittl JA: Major hemorrhage is an independent predictor of 1 year mortality following percutaneous coronary intervention: an analysis from REPLACE‐2. Am J Cardiol 2004; 946(1): 39E. [DOI] [PubMed] [Google Scholar]
  • 27. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, et al.: Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200–1206. [DOI] [PubMed] [Google Scholar]
  • 28. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555–1562. [DOI] [PubMed] [Google Scholar]
  • 29. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, et al.: Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994–998. [DOI] [PubMed] [Google Scholar]
  • 30. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al., REPLACE‐2 Investigators : Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE‐2 randomized trial. JAMA 2003; 289: 853–863. [DOI] [PubMed] [Google Scholar]
  • 31. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al., ACUITY Investigators : Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–2216. [DOI] [PubMed] [Google Scholar]
  • 32. Stone GW. A prospective, randomized trial of bivalirudin in acute coronary syndromes: final one‐year results from the ACUITY trial. Presented at: 56th Annual Session of the American College of Cardiology; March 26, 2007; New Orleans, LA, Available at: http:// www.cardiosource.com/annualmtg /acc07/Lectures.asp?sessiontitle = LateBreaking%20Clinical%20 Trials %20Follow‐Up&SessionID = 22&date = 3/26/2007 Accessed April 1, 2007.

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES